51.26
0.28 (0.55%)
| Previous Close | 50.98 |
| Open | 49.47 |
| Volume | 705,647 |
| Avg. Volume (3M) | 1,221,146 |
| Market Cap | 4,062,713,600 |
| Price / Earnings (TTM) | 7.87 |
| Price / Earnings (Forward) | 6.37 |
| Price / Sales | 2.29 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | 33.56% |
| Operating Margin (TTM) | 82.43% |
| Diluted EPS (TTM) | 6.51 |
| Quarterly Revenue Growth (YOY) | 459.70% |
| Current Ratio (MRQ) | 3.89 |
| Operating Cash Flow (TTM) | 691.65 M |
| Levered Free Cash Flow (TTM) | 526.00 M |
| Return on Assets (TTM) | 24.42% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | PTC Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | 4.0 |
| Average | 0.13 |
|
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.42% |
| % Held by Institutions | 101.06% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 112.00 (Cantor Fitzgerald, 118.49%) | Buy |
| Median | 66.50 (29.73%) | |
| Low | 40.00 (Citigroup, -21.97%) | Hold |
| Average | 65.88 (28.52%) | |
| Total | 6 Buy, 2 Hold | |
| Avg. Price @ Call | 42.30 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 27 May 2025 | 74.00 (44.36%) | Buy | 47.86 |
| B of A Securities | 09 May 2025 | 68.00 (32.66%) | Buy | 44.23 |
| Barclays | 08 May 2025 | 42.00 (-18.06%) | Hold | 42.51 |
| Baird | 07 May 2025 | 66.00 (28.76%) | Buy | 40.76 |
| Cantor Fitzgerald | 07 May 2025 | 112.00 (118.49%) | Buy | 40.76 |
| Citigroup | 07 May 2025 | 40.00 (-21.97%) | Hold | 40.76 |
| JP Morgan | 07 May 2025 | 67.00 (30.71%) | Buy | 40.76 |
| 31 Mar 2025 | 75.00 (46.31%) | Buy | 50.96 | |
| RBC Capital | 07 May 2025 | 58.00 (13.15%) | Buy | 40.76 |
| 22 Apr 2025 | 65.00 (26.80%) | Buy | 48.19 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 May 2025 | Announcement | PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results |
| 05 May 2025 | Announcement | PTC518 PIVOT-HD Study Achieves Primary Endpoint |
| 01 May 2025 | Announcement | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 25 Apr 2025 | Announcement | PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) |
| 24 Apr 2025 | Announcement | PTC Therapeutics to Participate at Upcoming Investor Conferences |
| 17 Apr 2025 | Announcement | PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results |
| 28 Mar 2025 | Announcement | PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe |
| 28 Mar 2025 | Announcement | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 20 Mar 2025 | Announcement | PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |